search
Back to results

Influence of Aging on Perioperative Methadone Dosing

Primary Purpose

Pain, Postoperative, Opioid Use, Methadone Overdose of Undetermined Intent

Status
Unknown status
Phase
Phase 4
Locations
Chile
Study Type
Interventional
Intervention
Methadone Injectable Product
Sponsored by
Pontificia Universidad Catolica de Chile
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring Methadone, Elderly, Postoperative Pain

Eligibility Criteria

18 Years - 105 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Over 18 years.
  2. ASA I, II or III.
  3. Laparoscopic Abdominal Surgery.

Exclusion Criteria:

  1. BMI> 35
  2. Use of opioids up to 5 days before surgery.
  3. Acute Liver Failure or Chronic Liver Damage Child C.
  4. Kidney damage with creatinine clearance estimated by Cockcroft-Gault formula <60 ml/min.

Sites / Locations

  • Pontificia Universidad Católica de ChileRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

Methadone 0

Methadone 1

Methadone 2

Methadone 3

Arm Description

Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered the placebo drug.

Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.05 mg/kg.

Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.1 mg/kg.

Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.2 mg/kg.

Outcomes

Primary Outcome Measures

Methadone plasmatic levels Measured by high pressure liquid chromatography
Five venous blood samples will be taken from each patient for methadone plasmatic level analysis. Patients will be randomly divided into two groups with different sample collection times. Group 1 at 0.05, 0.75, 1.5, 6, 18 hours post drug administration and Group 2 at 0.25, 1, 3, 12 and 24 hours.

Secondary Outcome Measures

Hemodynamics
Non invasive systolic and diastolic blood pressure monitoring (mmHg).
Heart Rate
Heart rate (bpm)
Pulse oximetry
% oximetry saturation
BIS
Depth of anesthesia will be recorded with BIS monitor. From 60 - 40
Respiratory rate
bpm
Numeric Pain Rating Scale
Numeric Pain rating scale in rest and movement, from 0 (no pain) to 10 (maximum pain).
Nausea or vomiting
Presence of nausea or vomiting in the recovery room.
Sedation (Ramsay Scale)
Ramsay scale (1-6)
Respiratory depression
Presence of respiratory depression in the recovery room. (Respiratory rate less than 8 bpm requiring oxygen therapy).
Other opioids and pain management drugs used during recovery stay
Name and total doses, including Morphine PCA.
Intestinal transit recovery
Time to first flatus, fist bowel movement and stool. Presence of abdominal bloating.

Full Information

First Posted
August 5, 2020
Last Updated
March 30, 2021
Sponsor
Pontificia Universidad Catolica de Chile
search

1. Study Identification

Unique Protocol Identification Number
NCT04526236
Brief Title
Influence of Aging on Perioperative Methadone Dosing
Official Title
Influence of Aging on Perioperative Methadone Dosing
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Unknown status
Study Start Date
September 9, 2019 (Actual)
Primary Completion Date
August 1, 2021 (Anticipated)
Study Completion Date
September 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pontificia Universidad Catolica de Chile

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Increasingly, elderly patients undergo anesthesia and surgery. Methadone is a great opioid for perioperative pain management, however, to date there are no pharmacokinetic or pharmacodynamic studies that asses a methadone dose adjustment in the elderly patient. The present study is aimed to characterize the pharmacokinetic and pharmacodynamic age-related changes of methadone in the adult population and further to design reference dosing protocols for intraoperative methadone use according to patient age.
Detailed Description
The subjects will be recruited from adult patients who undergo elective laparoscopic abdominal surgery at UC Christus Clinical Hospital (Santiago, de Chile). Patients will be randomly divided into four groups according to the dose of intravenous methadone to be administered during anaesthetic induction. BIS-guided and standard general anaesthesia will be administered with routine monitoring. Methadone will be administered once the patient is intubated and has hemodynamic stability. The only opioids that patients will receive will be remifentanil and methadone. Upon admission to the Post-anesthesia care unit, the patient is given a Patient-Control Analgesia pump for intravenous administration of morphine. Clinic evaluations will be carried out periodically and blood samples for measurement of plasma methadone will be taken at different times. Samples will be analyzed using high-performance liquid chromatography spectrofluorometric method. The data obtained will be collected in a form within the REDCAP application, to subsequently generate an encrypted database. Groups will be compared regarding pain score, drugs used, opioid consumption, side effects, time of recovery, and patient satisfaction. One, two and three-compartment linear models will be used to fit the plasma methadone concentration data over time. Models are parameterized in terms of elimination clearance, compartment distribution clearance, central volume and peripheral volume of distribution, as appropriate. The use of rescue morphine in the Post-anesthesia care unit will be used as a measure to relate the methadone dose (mg/kg) with the analgesic efficacy using an EMAX model. The data will be modelled using NONMEM VII. A proportional term will be used for variability between subjects. Additive and proportional terms will be used to characterize the unknown residual variability. Sample size calculations were estimated using a simulation-based approach and previous work with a similar methodology. To achieve an adequate representation of all age groups 60 patients will be required, distributed among 20 patients between 18 and 40 years, 20 patients between 41 and 65 years, and 20 patients> 65 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Opioid Use, Methadone Overdose of Undetermined Intent
Keywords
Methadone, Elderly, Postoperative Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomly divided into four groups according to the dose of intravenous methadone to be administered during anesthetic induction, for a total number of 60 patients.
Masking
ParticipantCare Provider
Masking Description
The masking will be generated on a research laboratory computer and will be stored in an encrypted file. This information will be known exclusively to a member of the research team present during the surgery, who will hand over preparing the corresponding medicine in a 20 cc syringe and hand it over to the treating anesthesiologist.
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Methadone 0
Arm Type
Placebo Comparator
Arm Description
Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered the placebo drug.
Arm Title
Methadone 1
Arm Type
Experimental
Arm Description
Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.05 mg/kg.
Arm Title
Methadone 2
Arm Type
Experimental
Arm Description
Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.1 mg/kg.
Arm Title
Methadone 3
Arm Type
Experimental
Arm Description
Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.2 mg/kg.
Intervention Type
Drug
Intervention Name(s)
Methadone Injectable Product
Other Intervention Name(s)
Methadone 0, Methadone 1 0,05 mg/kg, Methadone 2 0,1 mg/kg, Methadone 3 0,2 mg/kg
Intervention Description
Perioperative use of placebo for pain management and remifentanil during the surgery.
Primary Outcome Measure Information:
Title
Methadone plasmatic levels Measured by high pressure liquid chromatography
Description
Five venous blood samples will be taken from each patient for methadone plasmatic level analysis. Patients will be randomly divided into two groups with different sample collection times. Group 1 at 0.05, 0.75, 1.5, 6, 18 hours post drug administration and Group 2 at 0.25, 1, 3, 12 and 24 hours.
Time Frame
From the first dose up to 24 hours.
Secondary Outcome Measure Information:
Title
Hemodynamics
Description
Non invasive systolic and diastolic blood pressure monitoring (mmHg).
Time Frame
Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. Then, from the entrance to the recovery room every 30 minutes up to 180 minutes.
Title
Heart Rate
Description
Heart rate (bpm)
Time Frame
Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. Then, from the entrance to the recovery room every 30 minutes up to 180 minutes.
Title
Pulse oximetry
Description
% oximetry saturation
Time Frame
Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. Then, from the entrance to the recovery room every 30 minutes up to 180 minutes.
Title
BIS
Description
Depth of anesthesia will be recorded with BIS monitor. From 60 - 40
Time Frame
Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs.
Title
Respiratory rate
Description
bpm
Time Frame
Every 30 minutes. Since entering the recovery room up to 180 mins.
Title
Numeric Pain Rating Scale
Description
Numeric Pain rating scale in rest and movement, from 0 (no pain) to 10 (maximum pain).
Time Frame
Every 30 minutes. Since entering the recovery room up to 180 mins.
Title
Nausea or vomiting
Description
Presence of nausea or vomiting in the recovery room.
Time Frame
Every 30 minutes. Since entering the recovery room up to 180 mins.
Title
Sedation (Ramsay Scale)
Description
Ramsay scale (1-6)
Time Frame
Every 30 minutes. Since entering the recovery room up to 180 mins.
Title
Respiratory depression
Description
Presence of respiratory depression in the recovery room. (Respiratory rate less than 8 bpm requiring oxygen therapy).
Time Frame
Every 30 minutes. Since entering the recovery room up to 180 mins.
Title
Other opioids and pain management drugs used during recovery stay
Description
Name and total doses, including Morphine PCA.
Time Frame
Since the admission to the recovery room up to 2 hours.
Title
Intestinal transit recovery
Description
Time to first flatus, fist bowel movement and stool. Presence of abdominal bloating.
Time Frame
Since the admission to the recovery room up to 2 hours.
Other Pre-specified Outcome Measures:
Title
Body fat
Description
Body fat (kilograms) by body impedance analysis.
Time Frame
Once, before the anesthetic induction in the operating toom.
Title
Level of satisfaction with pain management: 10-point scale
Description
10-point scale: very unsatisfied to very satisfied.
Time Frame
Since the admission to the recovery room up to 2 hours.
Title
Lean Mass
Description
Lean mass (kilograms) by body impedance analysis.
Time Frame
Once, before the anesthetic induction in the operating toom.
Title
Total water
Description
Total water (kilograms) by body impedance analysis.
Time Frame
Once, before the anesthetic induction in the operating toom.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
105 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Over 18 years. ASA I, II or III. Laparoscopic Abdominal Surgery. Exclusion Criteria: BMI> 35 Use of opioids up to 5 days before surgery. Acute Liver Failure or Chronic Liver Damage Child C. Kidney damage with creatinine clearance estimated by Cockcroft-Gault formula <60 ml/min.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Victor Contreras, MSN
Phone
2223439217
Email
vecontre@uc.cl
First Name & Middle Initial & Last Name or Official Title & Degree
Maria F Elgueta, MD
Phone
222343270
Email
panchielgueta@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria F Elgueta, MD
Organizational Affiliation
Associate Professor
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pontificia Universidad Católica de Chile
City
Santiago
State/Province
Metropolitana
ZIP/Postal Code
8320000
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Victor Contreras, MSN
Phone
+5698420525
First Name & Middle Initial & Last Name & Degree
María F. Elgueta, MD
Phone
+56962187863
Email
panchielgueta@gmail.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
12817914
Citation
Sadean MR, Glass PS. Pharmacokinetics in the elderly. Best Pract Res Clin Anaesthesiol. 2003 Jun;17(2):191-205. doi: 10.1016/s1521-6896(03)00002-8.
Results Reference
background
PubMed Identifier
10934997
Citation
Shafer SL. The pharmacology of anesthetic drugs in elderly patients. Anesthesiol Clin North Am. 2000 Mar;18(1):1-29, v. doi: 10.1016/s0889-8537(05)70146-2.
Results Reference
background
PubMed Identifier
9009935
Citation
Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, Billard V, Hoke JF, Moore KH, Hermann DJ, Muir KT, Mandema JW, Shafer SL. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997 Jan;86(1):10-23. doi: 10.1097/00000542-199701000-00004.
Results Reference
background
PubMed Identifier
10360845
Citation
Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goodale DB, Youngs EJ. The influence of age on propofol pharmacodynamics. Anesthesiology. 1999 Jun;90(6):1502-16. doi: 10.1097/00000542-199906000-00003.
Results Reference
background
PubMed Identifier
17521291
Citation
Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007 Jun;21(3):217-30. doi: 10.1111/j.1472-8206.2007.00473.x.
Results Reference
background
PubMed Identifier
7132470
Citation
Kaiko RF, Wallenstein SL, Rogers AG, Grabinski PY, Houde RW. Narcotics in the elderly. Med Clin North Am. 1982 Sep;66(5):1079-89. doi: 10.1016/s0025-7125(16)31383-9. No abstract available.
Results Reference
background
PubMed Identifier
3377944
Citation
Singleton MA, Rosen JI, Fisher DM. Pharmacokinetics of fentanyl in the elderly. Br J Anaesth. 1988 May;60(6):619-22. doi: 10.1093/bja/60.6.619.
Results Reference
background
PubMed Identifier
3919613
Citation
Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 1985 Mar;62(3):234-41. doi: 10.1097/00000542-198503000-00005.
Results Reference
background
PubMed Identifier
19207240
Citation
Gallagher R. Methadone: an effective, safe drug of first choice for pain management in frail older adults. Pain Med. 2009 Mar;10(2):319-26. doi: 10.1111/j.1526-4637.2008.00551.x. Epub 2009 Jan 16.
Results Reference
background
PubMed Identifier
16431829
Citation
Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2005;19(4):13-24.
Results Reference
background
PubMed Identifier
14657982
Citation
Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag. 2003 Fall;8(3):149-54. doi: 10.1155/2003/236718.
Results Reference
background

Learn more about this trial

Influence of Aging on Perioperative Methadone Dosing

We'll reach out to this number within 24 hrs